- Home
- UHS vs EXEL Comparison
UHS vs EXEL Comparison
Compare UHS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHS | EXEL |
|---|---|---|
| Founded | 1978 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | UHS | EXEL |
|---|---|---|
| Price | $231.02 | $44.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 24 |
| Target Price | ★ $232.58 | $44.73 |
| AVG Volume (30 Days) | 663.8K | ★ 2.5M |
| Earning Date | 10-27-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | 39.76 | ★ 53.55 |
| EPS | ★ 21.01 | 2.38 |
| Revenue | ★ $16,992,503,000.00 | $2,288,218,000.00 |
| Revenue This Year | $10.93 | $9.14 |
| Revenue Next Year | $4.96 | $12.51 |
| P/E Ratio | ★ $11.00 | $18.67 |
| Revenue Growth | ★ 10.21 | 9.93 |
| 52 Week Low | $152.33 | $31.90 |
| 52 Week High | $246.33 | $49.62 |
Technical Indicators
Market Signals| Indicator | UHS | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 63.52 |
| Support Level | $228.00 | $43.00 |
| Resistance Level | $246.33 | $44.79 |
| Average True Range (ATR) | 5.99 | 1.03 |
| MACD | -1.35 | 0.06 |
| Stochastic Oscillator | 37.86 | 83.48 |
Price Performance
Historical ComparisonAbout UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.